Seagen (NASDAQ:SGEN) will be releasing its earnings data after the market closes on Thursday, July 29th. Analysts expect Seagen to post earnings of ($0.59) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Seagen (NASDAQ:SGEN) last released its quarterly earnings results on Thursday, April 29th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by ($0.08). The firm had revenue of $331.98 million during the quarter, compared to analysts' expectations of $341.39 million. Seagen had a return on equity of 21.41% and a net margin of 29.07%. On average, analysts expect Seagen to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
SGEN stock opened at $143.60 on Thursday. The stock has a market cap of $26.06 billion, a P/E ratio of 39.78 and a beta of 0.86. Seagen has a 1 year low of $133.20 and a 1 year high of $213.94. The business has a fifty day moving average price of $152.12.
A number of equities analysts have recently issued reports on the company. Evercore ISI assumed coverage on Seagen in a research note on Monday, May 17th. They issued an "inline" rating and a $153.00 price target on the stock. Piper Sandler dropped their price target on Seagen from $170.00 to $160.00 and set a "neutral" rating on the stock in a research note on Friday, April 30th. Morgan Stanley dropped their price target on Seagen from $173.00 to $167.00 and set an "equal weight" rating on the stock in a research note on Friday, July 16th. Credit Suisse Group assumed coverage on Seagen in a research note on Tuesday, March 30th. They issued a "neutral" rating and a $145.00 price target on the stock. Finally, Needham & Company LLC assumed coverage on Seagen in a report on Friday, April 30th. They issued a "buy" rating and a $254.00 target price on the stock. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Seagen presently has a consensus rating of "Buy" and an average target price of $185.92.
In other Seagen news, insider Vaughn B. Himes sold 1,303 shares of the firm's stock in a transaction dated Monday, June 7th. The stock was sold at an average price of $150.00, for a total transaction of $195,450.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Charles R. Romp sold 703 shares of the firm's stock in a transaction dated Friday, July 2nd. The shares were sold at an average price of $158.41, for a total value of $111,362.23. The disclosure for this sale can be found here. Over the last three months, insiders have sold 113,181 shares of company stock worth $16,467,175. Insiders own 27.60% of the company's stock.
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
See Also: What are popular green investing opportunities?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Seagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seagen wasn't on the list.
While Seagen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here